Carvedilol and Alverine in Portal Hypertension

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 15, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Hypertension, Portal
Interventions
DRUG

Carvedilol and alverine

On the basis of maintaining unchanged routine hepatoprotective and symptomatic supportive treatments and the original dose of carvedilol, participants will be administered with compound alverine citrate capsules (Le Jian Su; specification: each capsule contains alverine citrate 60 mg and simeticone 300 mg; manufactured by Laboratoires MAYOLY SPINDLER), at a dosage of 180 mg/day (1 capsule orally, 3 times a day), for a continuous period of 24 weeks.

All Listed Sponsors
collaborator

Shanghai East Hospital

OTHER

collaborator

Army Medical Center of PLA

OTHER_GOV

lead

Shanghai Changzheng Hospital

OTHER